Antisense polynucleotide inhibition of human growth factor-sensi

Details Antisense polynucleotide inhibition of human growth factor-sensi Antisense polynucleotide inhibition of human growth factor-sensi

1996-10-17

1999-04-06

Marschel, Ardin H.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

435 6, 435 691, 436501, 536 231, 536 241, 536 243, 536 2431, 536 2432, 536 2433, 935 77, 935 78, A01N 4304

Patent

active

058918582

ABSTRACT:
Antisense polynucleotides to human transforming growth factor alpha (TGF-.alpha.) and the receptor for human epidermal growth factor (rEGF) are disclosed. Those polynucleotides are about 30 to about 50 bases in length and each hybridizes to about 10 to about 25 bases flanking the start codon for the gene encoding those proteins. Use of those antisense polynucleotides alone, together and mixed with an antibody combining site-containing molecule that binds to rEGF in treating human growth factor-sensitive cancerous tumors such as prostate tumors is also disclosed.

REFERENCES:
patent: 4740463 (1988-04-01), Weinberg et al.
patent: 4816561 (1989-03-01), Todaro
patent: 4863899 (1989-09-01), Todaro
patent: 4999421 (1991-03-01), Brunck et al.
patent: 5004810 (1991-04-01), Draper
patent: 5087617 (1992-02-01), Smith
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5107065 (1992-04-01), Shewmaker et al.
patent: 5132408 (1992-07-01), Baird et al.
patent: 5135917 (1992-08-01), Burch
Sizeland et al. (1992), Molecular Biology of the Cell, vol. 3, No. 11, pp. 1235-1243.
Stein et al. (1993) Science, vol. 261, pp. 1004-1012.
New England Biolabs 1986/87 Catalog, pp. 60-62.
Rubenstein et al., Poster No. 31, 1992 International Symposium on Biology of Prostate Growth, National Institute of Diabetes, and Digestive and Kidney Diseases, (Sep. 11-13, 1992), Bethesda, MD.
Rubenstein et al., Society For Basic Urologic Research, 1992 Annual Fall Symposium (Oct. 3-6, 1992), St. Louis, MO.
Stedman's Medical Dictionary, 22nd ed., The Williams and Wilkins Co., Baltimore (1972) pp. 204, 205, 421, 468, and 1119.
Journal of Cellular Biology, Supplement 17E, 1993, Abstracts S022 (p. 191) and S027 (p. 192) and Arnold et al. (no page number), 1993.
Wilding, The Prostate,15:1-12 (1989).
Rubenstein et al., Clin. Physiol. Biochem., 9:47-50 (1992).
Aaronson et al., In: Molecular Foundations of Oncology, S. Broder (ed.), Williams and Wilkins, Baltimore, MD., pp. 27-39, (1991).
Todd et al, J. Dent. Res., 70:917-923 (1991).
Marshall et al., Science, 259: 1564-1570 (1993).
Gutierrez et al., The Lancet, 359:715-721 (1992).
Naraganan et al., Oncogene, 7:553-561 (1992).
Ullrich et al., Nature, 307:418-425 (1984).
Tseng et al, Cancer Gene Therapy, 1:65-71 (1994).
Vander Krol et al, Biotechniques, 6:958-976 (1988).
Hunts et al, FEBS Let., 206,319-322 (1986).
Baserga et al, Ann. NY Acad. Sci, 600:64-69 (1992).
Neckers et al, Ann. NY Acad. Sci, 600:37-44 (1992).

Affiliated with

Also associated with

Rating

Antisense polynucleotide inhibition of human growth factor-sensi does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense polynucleotide inhibition of human growth factor-sensi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense polynucleotide inhibition of human growth factor-sensi will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1371460